Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > TECH Bio-Techne > Detailed Quotes

TECH Bio-Techne

308.560
+15.490+5.29%
Close 10/04 16:00 ET
308.5600.0000.00%
Post Mkt Price 10/04 16:02 ET
High
308.800
Open
297.950
Turnover
100.65M
Low
297.950
Pre Close
293.070
Volume
328.76K
Market Cap
12.10B
P/E(TTM)
46.54
52wk High
530.109
Shares
39.22M
P/E(Static)
46.54
52wk Low
281.415
Float Cap
12.02B
Bid/Ask %
0.00%
Historical High
542.121
Shs Float
38.94M
Volume Ratio
1.19
Historical Low
4.699
Dividend TTM
1.28
Div Yield TTM
1.28
P/B
7.11
Dividend LFY
0.41%
Div Yield LFY
0.41%
Turnover Ratio
0.84%
Amplitude
3.70%
Avg Price
306.145
Lot Size
1
Float Cap
12.02B
Bid/Ask %
0.00%
Historical High
542.121
Shs Float
38.94M
Volume Ratio
1.19
Historical Low
4.699
Dividend TTM
1.28
P/B
7.11
Dividend LFY
0.41%
Turnover Ratio
0.84%
Amplitude
3.70%
Avg Price
306.145
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded in 1976 and is headquartered in Minneapolis, MN.
CEO: Mr. Charles R. Kummeth
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...